# Immunosuppression in Renal Transplantation

## Overview

Post-transplant immunosuppression represents a delicate balance between preventing allograft rejection and minimizing drug toxicity and infection risk. Modern immunosuppressive regimens achieve excellent short-term outcomes (\>95% one-year graft survival in living-donor kidneys) but long-term challenges—chronic kidney disease in the graft, late acute rejection, CNI toxicity, and malignancy—persist. Understanding the mechanism of action, drug interactions, therapeutic drug monitoring (TDM), and non-adherence as the \#1 cause of late graft loss is essential for nephrologists managing transplant patients.

High-Yield Board Point

**Induction therapy:** Basiliximab (IL-2 antagonist) or ATG (antithymocyte globulin) ± alemtuzumab. **Maintenance triple therapy (standard):** Calcineurin inhibitor (tacrolimus preferred over cyclosporine; target trough 8–12 ng/mL year 1, 6–10 ng/mL year 2+) + mycophenolate mofetil (1–3 g/day) + prednisone (taper to 5–10 mg/day). **Key challenges:** CNI nephrotoxicity (dose-dependent), non-adherence (leading cause of late graft loss), BK virus (polyomavirus), PTLD (post-transplant lymphoproliferative disorder), malignancy. **TDM critical:** Tacrolimus has narrow therapeutic window; target levels individualized.

### Historical Evolution

| Era | Regimen | 1-Year Graft Survival | 5-Year Graft Survival |
|----|----|----|----|
| Pre-1980s | Azathioprine + prednisone | ~70% | ~40% |
| Cyclosporine Era (1980s–2000s) | Cyclosporine + azathioprine + prednisone | ~85% | ~65% |
| Modern Era (2000s–present) | Tacrolimus + MMF + prednisone + induction | ~96% (living-donor) | ~70–75% |

## Immunologic Principles

### Allograft Rejection Mechanisms

#### Acute Cellular Rejection (ACR)

- T-cell mediated; CD8+ cytotoxic T cells and CD4+ helper T cells infiltrate graft
- Results from insufficient CNI/antimetabolite therapy
- Incidence: 10–20% in modern series (down from 40–60% in 1990s)
- Often reversible with pulse steroids or antibody therapy

#### Acute Antibody-Mediated Rejection (AMR)

- Humoral immune response; donor-specific antibodies (DSA) bind HLA/non-HLA antigens
- Complement activation (C4d deposition in peritubular capillaries); endothelial injury
- More refractory to treatment than ACR
- De novo DSA formation: 5–10% per year post-transplant

#### Chronic Rejection

- Combination of cellular and humoral alloimmunity
- Pathology: Chronic allograft nephropathy (CAN) — intimal fibrosis, glomerular sclerosis
- Progressive graft dysfunction (proteinuria, GFR decline)
- Often irreversible; leads to late graft loss

### Mechanisms of Key Agents

#### Calcineurin Inhibitors (CNI)

- Tacrolimus and cyclosporine inhibit calcineurin phosphatase
- Calcineurin normally dephosphorylates NFAT (nuclear factor of activated T cells)
- CNI blockade → NFAT remains phosphorylated → stays in cytoplasm → cannot enter nucleus
- Result: Reduced IL-2 transcription → T cell proliferation inhibited

#### Mycophenolate Mofetil (MMF)

- Prodrug of mycophenolic acid (MPA)
- Selectively inhibits inosine monophosphate dehydrogenase (IMPDH) type II
- IMPDH type II preferentially expressed in lymphocytes
- Inhibition → reduced guanosine synthesis → reduced lymphocyte proliferation
- **Selective for T and B cells** (other cell types use salvage pathway)

## Induction Therapy

### IL-2 Receptor Antagonists

| Agent | Mechanism | Dosing | Advantages | Disadvantages |
|----|----|----|----|----|
| **Basiliximab** | Chimeric monoclonal Ab to IL-2R alpha chain | 20 mg day 0, day 4 | Well-tolerated; minimal systemic effects | Less effective in high-risk; fewer infections |

### T-Cell Depleting Agents

#### Antithymocyte Globulin (ATG, rabbit)

- Polyclonal antibody; depletes T cells
- **Dosing:** 1.5 mg/kg/day × 3–5 days
- More potent than basiliximab; greater T-cell depletion
- **Side effects:** Cytokine release syndrome (fever, chills, myalgia; mitigated by slow infusion)
- **Risk:** Increased infection (CMV), PTLD from over-immunosuppression

#### Alemtuzumab

- Anti-CD52 monoclonal antibody; profound T and B cell depletion
- **Dosing:** 30 mg on day 0 and day 1 (typical)
- Most potent depletion; excellent for high-risk patients
- **Risk:** Very high infection/PTLD risk (requires close monitoring, CMV prophylaxis)
- Reduced maintenance immunosuppression often possible

#### Clinical Pearl

**Induction agent selection depends on immunologic risk:** High-risk (retransplant, prior sensitization, PRA \>50%) → T-cell depleting agent (ATG or alemtuzumab). Low-risk, older age, CMV+ → basiliximab. Standard induction: basiliximab (low-risk) vs. ATG (high-risk).

## Maintenance Immunosuppression: Triple Therapy

### Component 1: Calcineurin Inhibitor

#### Tacrolimus (Preferred)

- **Mechanism:** CNI; more selective for T cells than cyclosporine
- **Dosing:** Initial 0.1–0.3 mg/kg/day divided BID; titrate to trough levels
- **Target trough levels:**
  - Year 1 post-transplant: **8–12 ng/mL** (peak efficacy window)
  - Year 2+: **6–10 ng/mL** (reduce toxicity while maintaining efficacy)
  - Some centers use lower targets (5–7 ng/mL) in stable patients
- **Monitoring:** Trough levels twice weekly initially, then weekly × 1 month, then every 1–3 months
- **Metabolism:** Hepatic (CYP3A4); highly protein-bound
- **Nephrotoxicity:** Dose-dependent; afferent arteriolar vasoconstriction and CAN
- **Advantages over cyclosporine:** Better graft survival (SYMPHONY trial), less HTN, easier TDM

#### Cyclosporine (Less Common)

- Older CNI; more nephrotoxic, more HTN induction, less T-cell selective
- Target trough 100–200 ng/mL (or C2 600–800 ng/mL)

### Component 2: Antimetabolite

#### Mycophenolate Mofetil (MMF)

- **Mechanism:** Selective IMPDH type II inhibitor; reduces lymphocyte proliferation
- **Dosing:** 1–3 g/day (divided BID or TID)
- **Efficacy:** Reduces acute rejection rate by ~50% compared to azathioprine
- **GI side effects:** Diarrhea (30–40%), nausea; manage with enteric-coated form
- **No TDM needed** (variable absorption); some use MPA AUC if severe GI issues

Warning

**MMF is teratogenic (category D).** Avoid in women of childbearing age or ensure reliable contraception. Switch to azathioprine prior to planned pregnancy.

### Component 3: Corticosteroids

- **Mechanism:** Nuclear transcription factor; suppresses IL-2, TNF-alpha, other cytokines
- **Initial dose:** 20–30 mg/day (day 0, post-transplant)
- **Taper schedule:**
  - Week 1: 20–30 mg/day
  - Month 1: 15 mg/day
  - Month 3: 10 mg/day
  - Month 6–12: 5 mg/day (maintenance)
- **Complications:** HTN, hyperglycemia, weight gain, osteoporosis, infection susceptibility

#### Clinical Pearl

**Steroid minimization/withdrawal:** Modern regimens attempt to taper prednisone to the lowest possible dose (5–10 mg/day) due to long-term toxicity, but complete withdrawal increases rejection risk. Risk-benefit individualized based on rejection history, DSA status, and patient factors.

## Newer/Alternative Immunosuppressive Agents

### mTOR Pathway Inhibitors

| Agent | Target Trough | Advantages | Disadvantages |
|----|----|----|----|
| **Sirolimus** | 5–10 ng/mL | No CNI nephrotoxicity; less HTN; anti-angiogenic (may reduce malignancy risk) | GI side effects, hyperlipidemia, interstitial pneumonitis (rare), impaired wound healing |
| **Everolimus** | 3–8 ng/mL | Better GI tolerability than sirolimus | Similar profile to sirolimus |

### Belatacept (Costimulation Blockade)

- **Mechanism:** CTLA-4-Ig fusion protein; blocks CD80/CD86 costimulatory molecules (prevents T-cell second signal)
- **Dosing:** IV 5 mg/kg on days 0, 4, 14, 28, 56, 84 (loading), then every 4 weeks maintenance
- **Advantages:** No CNI nephrotoxicity; potential reduced malignancy; good long-term graft survival
- **Disadvantages:** IV only (requires infusion center); PTLD risk if EBV-seronegative; higher early cellular rejection

## Therapeutic Drug Monitoring & Drug Interactions

### TDM Targets

| Drug | Target Level | Timing | Method | Year 1 Frequency |
|----|----|----|----|----|
| **Tacrolimus** | 8–12 ng/mL (Y1); 6–10 ng/mL (Y2+) | Pre-dose (trough) | LC-MS/MS (gold standard) | 2×/wk → weekly → biweekly → monthly |
| **Cyclosporine** | 100–200 ng/mL | Pre-dose | HPLC or LC-MS/MS | Similar |
| **Sirolimus** | 5–10 ng/mL | Pre-dose | LC-MS/MS | Similar to tacrolimus |
| **Everolimus** | 3–8 ng/mL | Pre-dose | LC-MS/MS | Similar to tacrolimus |

### Major CYP3A4 Interactions (Tacrolimus)

#### Inhibitors (Increase Tacrolimus Levels — Toxicity Risk)

- **Antibiotics:** Macrolides (erythromycin, azithromycin); fluoroquinolones
- **Antifungals:** Fluconazole, itraconazole, voriconazole (avoid if possible; reduce tacrolimus dose)
- **Antiretrovirals:** Ritonavir (boosting agent)
- **Other:** Cimetidine, diltiazem, verapamil, grapefruit juice

#### Inducers (Decrease Tacrolimus Levels — Subtherapeutic Risk)

- **Anticonvulsants:** Phenytoin, phenobarbital, carbamazepine
- **Antibiotics:** Rifampicin/rifampin (potent inducer; avoid)
- **Other:** St. John’s wort (herbal; avoid)

Warning: Generic Tacrolimus Formulations

Different generic formulations have different bioavailability. **Switching brands can cause subtherapeutic or toxic levels.** Maintain consistent formulation if possible. If switch unavoidable: close TDM (check trough 5–7 days post-switch); adjust dose as needed.

## Non-Adherence: The \#1 Cause of Late Graft Loss

### Epidemiology

- ~20–25% of renal transplant patients are non-adherent to immunosuppression
- Adherence worsens over time (years 3–5: 30–40% non-adherent)
- Non-adherence associated with **2–3× higher risk of graft loss**

### Causes of Non-Adherence

| Category | Examples |
|----|----|
| **Intentional** | Belief that reduced dose is safe; desire to “test” kidney; intentional missed doses |
| **Unintentional** | Forgetfulness; complex regimen; cost/insurance barriers; side effects |
| **Psychosocial** | Depression, anxiety, substance abuse, denial of transplant |
| **Side effects** | GI issues (MMF), HTN (CNI), tremor (CNI), acne (steroids) |
| **Access/cost** | Pharmacy access, medication cost, out-of-pocket expenses |

### Interventions to Improve Adherence

1.  **Education:** Emphasize graft dependence on immunosuppression; explain consequences
2.  **Simplification:** Once-daily formulations if possible; reduce number of agents
3.  **Reminder systems:** Phone alerts, pill organizers, pharmacy calls
4.  **Psychosocial support:** Mental health screening; intervention if depression/substance abuse
5.  **Cost assistance:** Pharmaceutical patient assistance programs; navigate insurance barriers
6.  **Frequent monitoring:** Close contact with transplant team; early identification

#### Clinical Pearl

**Late acute rejection (years 1–5)** is increasingly recognized as primarily due to non-adherence rather than immunologic failure. Always suspect non-adherence (check tacrolimus level) when acute rejection develops in a stable transplant patient. Non-adherence is preventable; intervention is critical.

## CNI Nephrotoxicity, Viral Complications, and Malignancy

### CNI Nephrotoxicity

#### Acute CNI Nephrotoxicity

- Dose-dependent; reversible
- **Mechanism:** Afferent arteriolar vasoconstriction; reduced GFR
- Manifests as rising creatinine with elevated trough levels
- May mimic acute rejection (distinguished by biopsy or CNI level reduction + Cr improvement)

#### Chronic CNI Nephrotoxicity (CAN)

- Cumulative, irreversible arteriolopathy/tubulointerstitial fibrosis
- **Pathology:** Tubular atrophy, interstitial fibrosis, arteriolar hyalinosis
- Develops despite “normal” trough levels (time-dependent)
- Contributes to long-term graft dysfunction

#### Management

1.  **Reduce CNI dose:** Decrease tacrolimus; check trough in 3–5 days; reassess Cr after 1–2 weeks
2.  **Switch CNI:** Cyclosporine to tacrolimus (or vice versa)
3.  **CNI-sparing regimen:** Add sirolimus or everolimus; reduce CNI dose while maintaining IS

#### Clinical Pearl

ACE-I/ARB are generally **protective** and should be used in renal transplant patients for HTN management and graft protection (reduce proteinuria, slow graft decline). Do NOT avoid ACE-I/ARB in transplant; monitor Cr/K+ but they are beneficial.

### BK Polyomavirus Nephropathy (BKVN)

- **Mechanism:** BK virus reactivation in immunocompromised patients; direct viral cytolysis of tubular epithelium
- **Incidence:** 1–5% of renal transplants (higher with tacrolimus than cyclosporine)
- **Presentation:** Asymptomatic rise in creatinine (months 3–12 post-transplant typical)
- **Diagnosis:**
  - Plasma BK viral load: \>100 copies/mL suggests viremia; \>1000 copies/mL concerning
  - Urine BK viral load: \>10⁷ copies/mL suggests active replication
  - Kidney biopsy: Nuclear inclusions, inflammation, fibrosis (confirms diagnosis)
- **Management:** Reduce immunosuppression (decrease CNI and/or antimetabolite); quarterly monitoring
- **Prognosis:** If caught early (low viral load), ~70% respond to reduced IS; if delayed, progressive graft loss likely

### Cytomegalovirus (CMV)

- **Risk:** ~20% of CMV-seronegative recipients of seropositive donor (D+/R-) without prophylaxis
- **Prophylaxis:** Valganciclovir 900 mg PO daily × 3–6 months (for D+/R- or high-risk)
- **Clinical disease:** Fever, leukopenia, viral syndrome, colitis, esophagitis (rare now with prophylaxis)

### Malignancy and PTLD Risk

#### Post-Transplant Lymphoproliferative Disorder (PTLD)

- Spectrum from benign lymphoid hyperplasia to frank lymphoma
- **EBV-associated (90% of cases):** Risk highest in EBV-seronegative recipients
- Risk increased with T-cell depleting induction (ATG, alemtuzumab \>\> basiliximab)
- **Incidence:** 1–2% in modern series; higher (5–10%) with alemtuzumab

#### Solid Malignancy

- Skin cancer: 20–40× higher (monitor skin regularly)
- Cervical cancer: HPV screening/vaccination recommended
- Lymphomas: EBV-related and non-EBV
- Lung, kidney, liver, colon cancers: 2–3× general population

Cancer Prevention in Transplant

Minimize immunosuppression over time (reasonable goal). Screen for cancer (skin exams, cervical cytology, colonoscopy per guidelines). Vaccinate pre-transplant (HPV vaccine) when possible. If EBV-seronegative, use less aggressive induction (basiliximab \> ATG); monitor EBV viral load in year 1.

## References

1.  Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9 Suppl 3:S1-S155. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19845597/)
2.  Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation (SYMPHONY trial). *N Engl J Med*. 2007;357(25):2562-2575. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18094377/)


---

[Website version](https://urinenephrology.org/mastery/transplant/immunosuppression.html) · Markdown synchronized October 3, 2026.